Olafsdottir Thorunn A, Alexandersson Kristjan F, Sveinbjornsson Gardar, Lapini Giulia, Palladino Laura, Montomoli Emanuele, Del Giudice Giuseppe, Gudbjartsson Daniel F, Jonsdottir Ingileif
deCODE Genetics, Amgen Inc., Reykjavik, Iceland.
Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Front Immunol. 2018 Jan 8;8:1872. doi: 10.3389/fimmu.2017.01872. eCollection 2017.
Influenza vaccination remains the best strategy for the prevention of influenza virus-related disease and reduction of disease severity and mortality. However, there is large individual variation in influenza vaccine responses. In this study, we investigated the effects of gender, age, underlying diseases, and medication on vaccine responses in 1,852 Icelanders of broad age range who received trivalent inactivated influenza virus vaccination in 2012, 2013, or 2015. Hemagglutination inhibition (HAI) and microneutralization (MN) titers were measured in pre- and post-vaccination sera. Of the variables tested, the strongest association was with level of pre-vaccination titer that explained a major part of the variance observed in post-vaccination titers, ranging from 19 to 29%, and from 7 to 21% in fold change (FC), depending on the strain and serological (HAI or MN) analysis performed. Thus, increasing pre-vaccination titer associated with decreasing FC ( = 1.1 × 10-8.6 × 10) and increasing post-vaccination titer ( = 2.1 × 10-1.1 × 10). Questionnaires completed by 87% of the participants revealed that post-vaccination HAI titer showed association with repeated previous influenza vaccinations. Gender had no effect on vaccine response whereas age had a strong effect and explained 1.6-3.1% of HAI post-vaccination titer variance and 3.1% of H1N1 MN titer variance. Vaccine response, both fold increase and seroprotection rate (percentage of individuals reaching HAI ≥ 40 or MN ≥ 20), was higher in vaccinees ≤37 years of age (YoA) than all other age groups. Furthermore, a reduction was observed in the H1N1 MN titer in people ≥63 YoA, demonstrating a decreased neutralizing functionality of vaccine-induced antibodies at older age. We tested the effects of underlying autoimmune diseases, asthma and allergic diseases and did not observe significant associations with vaccine responses. Intake of immune modulating medication did not show any association. Taken together, our results show that previous encounter of influenza vaccination or infection, reflected in high HAI and MN pre-vaccination titer has the strongest negative effect on vaccine responses measured as FC and the strongest positive effect on post-vaccination titer. Increasing age had also an effect but not gender, underlying disease or medication.
流感疫苗接种仍然是预防流感病毒相关疾病以及降低疾病严重程度和死亡率的最佳策略。然而,流感疫苗反应存在很大的个体差异。在本研究中,我们调查了性别、年龄、基础疾病和药物治疗对1852名年龄范围广泛的冰岛人的疫苗反应的影响,这些人在2012年、2013年或2015年接种了三价灭活流感病毒疫苗。在接种疫苗前后的血清中测量血凝抑制(HAI)和微量中和(MN)效价。在所测试的变量中,最强的关联是与接种前效价水平,其解释了接种后效价中观察到的大部分方差,范围从19%到29%,以及倍数变化(FC)中的7%到21%,这取决于所进行的毒株和血清学(HAI或MN)分析。因此,接种前效价增加与FC降低(=1.1×10 - 8.6×10)和接种后效价增加(=2.1×10 - 1.1×10)相关。87%的参与者填写的问卷显示,接种后HAI效价与之前重复接种流感疫苗有关。性别对疫苗反应没有影响,而年龄有很大影响,解释了接种后HAI效价方差的1.6 - 3.1%以及H1N1 MN效价方差的3.1%。年龄≤37岁的疫苗接种者的疫苗反应,无论是倍数增加还是血清保护率(HAI≥40或MN≥20的个体百分比),都高于所有其他年龄组。此外,在年龄≥63岁的人群中观察到H1N1 MN效价降低,表明在老年时疫苗诱导抗体的中和功能下降。我们测试了基础自身免疫性疾病、哮喘和过敏性疾病的影响,未观察到与疫苗反应的显著关联。免疫调节药物的摄入未显示出任何关联。综上所述,我们的结果表明,接种前HAI和MN效价高所反映的既往流感疫苗接种或感染经历,对以FC衡量的疫苗反应具有最强的负面影响,而对接种后效价具有最强的正面影响。年龄增加也有影响,但性别、基础疾病或药物治疗没有影响。